{"id":"785495960d1b","type":"article","url":"https://hartvaat.nl/2026/02/18/telomeerherstel-via-gentherapie-bij-cardiorenaal-syndroom-type-4/","title":"Telomeerherstel via gentherapie bij cardiorenaal syndroom type 4","title_en":"Telomere recapping via gene therapy as a beneficial strategy for cardio-renal syndrome type 4","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","vrouwen"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00130-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00130-4/fulltext","authors":["Danshu Xie","Chenguang Wang","Xin Wan","Longyu Wang","Yinlong Zhao","Jianan Pan","Yushu Zhao","Jiaying Ji","Jiaolun Li","Yangyang Liu","Feng Ding","Alex C.Y. Chang","Wei Ding"],"significance":4,"published":"2026-02-18","source_date":"2026-02-18","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This study investigated telomere recapping via gene therapy as a beneficial strategy for cardiorenal syndrome type 4, where heart failure is driven by chronic kidney disease. The approach addresses the shortened telomere lengths observed in advanced CKD patients.","created":"2026-07-03T10:25:19Z","updated":"2026-07-03T13:24:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Cardiorenaal syndroom type 4 is hartfalen veroorzaakt door chronische nierziekte. Cardiovasculaire mortaliteit is de belangrijkste doodsoorzaak bij gevorderd CKD. Dit onderzoek onderzocht telomeerherstel via gentherapie als potentiële strategie.","abstract_original":"Cardio-renal syndrome type 4 (CRS4) is defined as heart failure driven by chronic kidney disease (CKD). Cardiovascular mortality is the leading cause of death in patients with advanced CKD with current medical treatments exhibiting limited efficacy. Short leukocyte telomere lengths in such patients are correlated with increased mortality, particularly cardiovascular mortality. Here, we examined telomere shortening in mouse and human cardiomyocyte models of CRS4 and its potential protective role by overexpression of telomerase reverse transcriptase."}